Literature DB >> 26823880

Homocysteine, endothelin-1 and nitric oxide in patients with hypertensive disorders complicating pregnancy.

Yachang Zeng1, Mujun Li1, Yue Chen1, Sumei Wang1.   

Abstract

OBJECTIVE: To investigate the change of level of serum homocysteine (Hcy), endothelin-1 (ET-1) and nitric oxide (NO) and clinical significance in patients with HDCP.
METHODS: Two hundred and thirty nine patients with HDCP (137 patients with mild preeclampsia, 102 patients with severe preeclampsia) who were hospitalized between June 2012 and June 2015 and 200 normal pregnancy women in outpatient department were enrolled in our study were divided into HDCP group and control group. Serum Hcy concentration was measured by enzymatic cycling assay. ET-1 concentration was measured by enzyme linked immunosorbent assay. And no concentration was measured by nitrate reductase assay.
RESULTS: Serum Hcy and ET-1 in HDCP group were significantly higher as compared to control group (P<0.05). Level of serum NO in HDCP group was significantly lower than in the control group (P<0.05). Level of serum Hcy and ET-1 in mild and severe preeclampsia group were significantly higher as compared to control group, respectively (P<0.05). Level of serum NO in mild and severe preeclampsia group were significantly lower than in the control group' respectively (P<0.05). Level of serum Hcy and ET-1 in severe preeclampsia group were significantly higher as compared to mild preclampsia group (P<0.05). Level of serum NO in severe preeclampsia group were significantly lower than in mild preeclampsia group (P<0.05). Spearman rank correlation analysis showed that level of serum Hcy and ET-1 was positively correlated with severity of diseases (r=0.689, 0.718, P<0.05). Level of serum NO was negatively correlated with severity of diseases (r=-0.702, P<0.05).
CONCLUSION: Serum Hcy, ET-1 and NO were associated with pathogenesis of HDCP. Comprehensively measurement of them could effectively evaluate the incidence and progress of HDCP.

Entities:  

Keywords:  Gestational hypertension; endothelin-1; homocysteine; nitric oxide

Mesh:

Substances:

Year:  2015        PMID: 26823880      PMCID: PMC4713666     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  20 in total

1.  ER stress mediates homocysteine-induced endothelial dysfunction: Modulation of IKCa and SKCa channels.

Authors:  Xiang-Chong Wang; Wen-Tao Sun; Cheuk-Man Yu; Shun-Hay Pun; Malcolm John Underwood; Guo-Wei He; Qin Yang
Journal:  Atherosclerosis       Date:  2015-07-11       Impact factor: 5.162

2.  Hypertension in pregnancy is associated with elevated homocysteine levels later in life.

Authors:  Wendy M White; Stephen T Turner; Kent R Bailey; Thomas H Mosley; Sharon L R Kardia; Heather J Wiste; Iftikhar J Kullo; Vesna D Garovic
Journal:  Am J Obstet Gynecol       Date:  2013-06-19       Impact factor: 8.661

3.  [Genetic variability of endothelin-1 system in gestational hypertension and preeclampsia].

Authors:  Agnieszka Seremak-Mrozikiewicz; Magdalena Barlik; Michał Perlik; Grazyna Kurzawińska; Krzysztof Drews
Journal:  Ginekol Pol       Date:  2011-05       Impact factor: 1.232

4.  [The influence of vitamin C and E use on concentration of endothelin-1 and lipid peroxides in the serum of pregnant women with arterial hypertension].

Authors:  Jacek Pasiński; Arkadiusz Swierczewski; Dorota Estemberg; Urszula Kowalska-Koprek; Agata Karowicz-Bilińska
Journal:  Ginekol Pol       Date:  2013-01       Impact factor: 1.232

5.  Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1.

Authors:  Babbette LaMarca; Marc Parrish; Lillian Fournier Ray; Sydney R Murphy; Lyndsay Roberts; Porter Glover; Gerd Wallukat; Katrin Wenzel; Kathy Cockrell; James N Martin; Michael J Ryan; Ralf Dechend
Journal:  Hypertension       Date:  2009-08-24       Impact factor: 10.190

6.  [Relationship between neurokinin B and endothelin-1 and hypertensive disorders complicating pregnancy].

Authors:  Zhi-Min Li; Yun Zhao; Qian Chen; Li Zou; Ze-Hua Wang
Journal:  Zhonghua Fu Chan Ke Za Zhi       Date:  2008-08

7.  Genotype of the CYBA promoter -930A/G, polymorphism C677T of the MTHFR and APOE genotype in patients with hypertensive disorders of pregnancy: an observational study.

Authors:  Pablo Stiefel; María Luisa Miranda; Lola M Bellido; Jerónimo Luna; Luis Jiménez; Encarnación Pamies; Pablo García de Frutos; José Villar
Journal:  Med Clin (Barc)       Date:  2009-10-24       Impact factor: 1.725

8.  Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance.

Authors:  Sabine Perl; Isabella Schmölzer; Harald Sourij; Helga Pressl; Michaela Eder; Robert Zweiker; Thomas C Wascher
Journal:  Int J Cardiol       Date:  2008-12-31       Impact factor: 4.164

9.  [Effects of danshen on NO and ET-1 secreted by endothelial cells induced by the serum of pre-eclampsia patients].

Authors:  Zhong-fang Zhang; Bing Li; Dun-jin Chen
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2013-04

10.  Pregnancy-induced hypertension is accompanied by decreased number of circulating endothelial cells and circulating endothelial progenitor cells.

Authors:  Jerzy Heimrath; Maria Paprocka; Andrzej Czekanski; Agata Ledwozyw; Aneta Kantor; Danuta Dus
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2014-02-23       Impact factor: 4.291

View more
  12 in total

1.  Toll-like receptor 4 mutation suppresses hyperhomocysteinemia-induced hypertension.

Authors:  Anastasia Familtseva; Pankaj Chaturvedi; Anuradha Kalani; Nevena Jeremic; Naira Metreveli; George H Kunkel; Suresh C Tyagi
Journal:  Am J Physiol Cell Physiol       Date:  2016-08-03       Impact factor: 4.249

Review 2.  Altered Endothelial Nitric Oxide Signaling as a Paradigm for Maternal Vascular Maladaptation in Preeclampsia.

Authors:  George Osol; Nga Ling Ko; Maurizio Mandalà
Journal:  Curr Hypertens Rep       Date:  2017-09-23       Impact factor: 5.369

3.  Sildenafil Citrate Does Not Reprogram Risk of Hypertension and Chronic Kidney Disease in Offspring of Preeclamptic Pregnancies in the Dahl SS/Jr Rat.

Authors:  Hannah R Turbeville; Ashley C Johnson; Michael R Garrett; Jennifer M Sasser
Journal:  Kidney360       Date:  2020-04-17

4.  The expression profile of plasmatic exosomal lncRNAs in early-onset preeclampsia by sequencing.

Authors:  Xiaoqian Fu; Min Wu; Yue Chen; Liling Li; Hongyu Yin; Kaili Liang; Yachang Zeng
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

5.  Association between serum placental growth factor and vascular endothelial function in hyprtensive disorders complicating pregnancy.

Authors:  Weiling Li; Shasha Liu; Yuan Li; Weijing Wang; Yiming Dong; Lin Qi; Jie Ren; Jiefang Zhang
Journal:  Exp Biol Med (Maywood)       Date:  2021-12-14

6.  Reduced Intellectual Ability in Offspring Born from Preeclamptic Mothers: A Prospective Cohort Study.

Authors:  Linli Liu; Zhou Lin; Beihong Zheng; Lanlan Wang; Jianqin Zou; Sanshan Wu; Zhongqing Jiang; Qiong Jin; Xuedan Lai; Peihong Lin
Journal:  Risk Manag Healthc Policy       Date:  2020-10-08

Review 7.  Pre-eclampsia: pathogenesis, novel diagnostics and therapies.

Authors:  Elizabeth A Phipps; Ravi Thadhani; Thomas Benzing; S Ananth Karumanchi
Journal:  Nat Rev Nephrol       Date:  2019-05       Impact factor: 28.314

Review 8.  The Role of Nitric Oxide, ADMA, and Homocysteine in The Etiopathogenesis of Preeclampsia-Review.

Authors:  Weronika Dymara-Konopka; Marzena Laskowska
Journal:  Int J Mol Sci       Date:  2019-06-05       Impact factor: 5.923

Review 9.  Measurement of homocysteine: a historical perspective.

Authors:  Sreyoshi Fatima Alam; Santosh Kumar; Paul Ganguly
Journal:  J Clin Biochem Nutr       Date:  2019-10-08       Impact factor: 3.114

10.  Association of Cystathionine β-Synthase Gene Polymorphisms With Preeclampsia.

Authors:  Mercedes Piedad de León Bautista; Mirza Romero-Valdovinos; Beatriz Zavaleta-Villa; Arony Martínez-Flores; Angélica Olivo-Díaz
Journal:  Clin Appl Thromb Hemost       Date:  2018-10-31       Impact factor: 2.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.